


## Central African Republic

### Region: Central Africa

#### Key information on co-financing

- Gross National Income per capita (2017): \$ 390
- Co-financing status (2019): Initial self-financing  
Country is projected to stay in initial self-financing phase for next 5 years.




#### Immunisation financing

	2013	2014	2015	2016	2017
<b>Vaccines used in routine immunisation</b>					
- Government expenditure	\$ 64,772	\$ 155,065	\$ 69,865	\$ 124,244	\$ 115,961
- Total expenditure	\$ 2,640,268	\$ 3,495,031	\$ 4,449,284	\$ 2,806,695	\$ 2,164,449
- Government as % of total	2%	4%	2%	4%	5%
<b>Routine immunisation</b>					
- Government expenditure	\$ 137,497	\$ 155,065	\$ 69,865	\$ 124,244	\$ 168,359
- Total expenditure	\$ 2,842,537	\$ 8,919,080	\$ 6,902,389	\$ 5,189,738	\$ 2,905,217
- Government as % of total	5%	2%	1%	2%	6%

Source: WHO-UNICEF Joint Reporting Form 2017

Domestic General government expenditure on health as a share of gross domestic product: **2%**

#### Expenditure on routine immunisation in 2017



Source: WHO National Health Accounts, 2015

#### Gavi supported vaccines

Vaccines	Type	Year(s) of Gavi support	Co-financing required
Yellow Fever	Routine	2003-present	Yes
Pentavalent	Routine	2008-present	Yes
PCV	Routine	2011-present	Yes
IPV	Routine	2015-present	No
MenA	Routine	2017-present	Yes
MenA	Campaign	2017	No

#### Co-financing payments

Year	Total amount paid by the country	Co-financed vaccines			
		Vaccine	Year	Co-financing	
2008	\$ 41,000	Penta	Yellow Fever	-	
2009	\$ 92,000	Penta	Yellow Fever	-	
2010	\$ 68,000	Penta	Yellow Fever	-	
2011	\$ 101,000	Penta	Yellow Fever	PCV	
2012	\$ 187,000	Penta	Yellow Fever	PCV	
2013	\$ -	Penta	Yellow Fever	PCV	
2014	\$ 149,000	Penta	Yellow Fever	PCV	
2015	\$ 70,000	Penta	Yellow Fever	PCV	
2016	\$ 184,000	Penta	Yellow Fever	PCV	
2017	\$ 229,568	Penta	Yellow Fever	PCV	MenA
2018	\$ 251,466	Penta	Yellow Fever	PCV	MenA

\* In 2013, CAR's co-financing requirements were waived by the Board


\*\* amount allocated in May 2018 towards 2017 co-financing

## Co-financing obligations for 2019

	Co-financing obligations (in US\$)	Co-financing obligations (in doses)
Pentavalent	\$ 3,000	4,500
YF	\$ 34,000	27,800
MenA*	\$ -	-
PCV*	\$ -	-
<b>Total</b>	<b>\$ 37,000</b>	

\* country is receiving full Gavi support for 13-23 month cohort and has sufficient stocks for 0-12 months cohort, hence no co-financing obligation.

## Co-financing projections for 2020 - 2024



	2020	2021	2022	2023	2024
MenA Routine (fully self-financed)	\$ 30,772	\$ 31,899	\$ 32,881	\$ 33,889	\$ 34,902
PCV	\$ 70,946	\$ 74,324	\$ 77,242	\$ 80,240	\$ 83,276
M routine	\$ -	\$ -	\$ 4,293	\$ 54,437	\$ 74,040
Penta	\$ 79,730	\$ 83,526	\$ 86,805	\$ 90,175	\$ 93,587
<b>Total</b>	<b>\$ 181,448</b>	<b>\$ 189,750</b>	<b>\$ 204,717</b>	<b>\$ 258,741</b>	<b>\$ 285,804</b>

- Projections are based on Gavi's operational forecast version 16.
- These projections do not guarantee renewal of support or approval of country's application.
- Final co-financing obligations will be communicated through decision letters.